ELOX (Eloxx Pharmaceuticals) Other Financing: $9.39 Mil (TTM As of Dec. 2025)


ELOX Eloxx Pharmaceuticals Inc ELOX
17 GF Score
Price $11.56
! 2 Warning Signs
View Full Analysis

What is Eloxx Pharmaceuticals Other Financing?

Eloxx Pharmaceuticals ELOX -16.75% 17 Other Financing is $9.39 Mil as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

Eloxx Pharmaceuticals's Other Financing for the six months ended in Dec. 2025 was $9.39 Mil.

Eloxx Pharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $9.39 Mil.

Eloxx Pharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Other Financing Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.58 0.00 0.43 0.38 9.39

Eloxx Pharmaceuticals Semi-Annual Data
Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.58 0.00 0.43 0.38 9.39
ELOX
17GF Score
Eloxx Pharmaceuticals Inc ELOX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $9.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $9.39 Mil mean?
Eloxx Pharmaceuticals (ELOX) has a Other Financing of $9.39 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Eloxx Pharmaceuticals and its competitors.
Is Eloxx Pharmaceuticals' Other Financing too high?
Eloxx Pharmaceuticals' current Other Financing is $9.39 Mil. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' Other Financing compare to ESLA and RNXT?
Eloxx Pharmaceuticals' Other Financing of $9.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current Other Financing is $9.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current Other Financing of $9.39 Mil. The current Other Financing is $9.39 Mil. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current Other Financing is $9.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score

Get the complete analysis for ELOX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.56
Price